High Tide Inc (HITI) Fair Value & Analysis
Healthcare · CA · Market cap C$280M
Fair value as of: Jul 17, 2026
From 15 valuation models · updated 24 days ago
Fair value updated Jul 17, 2026, revised from C$3.17 to C$2.40 (−24.3%) since Jun 24, 2026. Share price +1.6% over the past month.
Below-average quality, and screening another 25% overvalued on our models.
What matters now
- Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (C$1.39 to C$3.15) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range C$1.44 – C$11.70 · fair‑value band C$1.39 – C$3.15 · the C$3.19 price screens above the C$2.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
High Tide Inc (HITI) currently trades at C$3.19, while our model-based Fair Value estimate is C$2.40, implying the stock looks roughly 24.8% overvalued today. The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, High Tide Inc generated revenue of C$630M at a net margin of -7.4%. Revenue grew 25.2% year over year. It earns a return on equity of -39.7%. Net debt stands at C$51.2M. Fundamentals as of Jul 17, 2026
Our scenario range runs from C$1.39 (bear case) to C$3.15 (bull case); at C$3.19, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -25%, HITI screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (C$3.19) versus Dividend Discount (C$0.2500). Highest evidence: Growth DCF (80).
Notify me when HITI reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 34 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
High Tide Inc. engages in the cannabis retail business in Canada, the United States, and internationally. The company operates through Bricks and Mortar, E-commerce, and Medical Cannabis Distribution segments. It manufactures and distributes consumption accessories; cannabis; and hemp derived products.
Full company description
High Tide Inc. engages in the cannabis retail business in Canada, the United States, and internationally. The company operates through Bricks and Mortar, E-commerce, and Medical Cannabis Distribution segments. It manufactures and distributes consumption accessories; cannabis; and hemp derived products. The company also engages in data analytics; advertising; product sourcing and imports; event-based cannabis retail; medical cannabis distribution; accessories retail; and other related services. It provides its products under the Daily High Club, DankStop, FAB CBD, GC, Nuleaf Naturals, Smoke Cartel, Blessed CBD, Fastendr, Famous Brandz, Queen of Bud, Canna Cabana, Grasscity, Daily High Club, and Valiant Distribution brands. The company sells its products through a network of retail stores, e-commerce platforms, and the wholesale distribution arm. The company was formerly known as High Tide Ventures Inc. and changed its name to High Tide Inc. in October 2018. The company was founded in 2009 and is headquartered in Calgary, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
High Tide Inc reported revenue of C$594M in FY2025 versus C$181M in FY2021, a compound +34.6%/yr. Reported net income was −C$50.7M in FY2025.
HITI screens 25% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare High Tide Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is High Tide Inc (HITI) overvalued or undervalued?
What is the fair value of HITI?
What is the quality score of HITI?
What is the revenue of High Tide Inc (HITI)?
What is the net profit margin of HITI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track High Tide Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.